Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2015

Open Access 01-12-2015 | Case report

Fixed drug eruption to sitagliptin

Authors: Mrinal Gupta, Anish Gupta

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2015

Login to get access

Abstract

Fixed drug eruption is a common adverse effect seen with various drugs notably antibiotics, antiepileptics and non-steroidal anti-inflammatory drugs. Herein we report a case of Sitagliptin induced fixed drug eruption in a 46 year old female who developed circumscribed, erythematous macules all over the body within one week of initiation of Sitagliptin. The lesions resolved with residual hyperpigmentation on cessation of the drug. The diagnosis was confirmed by an oral provocation test which led to a reactivation of the lesions. To the best of our knowledge, this is the first case of fixed drug eruption to Sitagliptin reported in the literature.
Literature
1.
go back to reference Desai S, Brinker A, Swann J, Iyasu S. Sitagliptin associated drug allergy: review of spontaneous adverse event reports. Arch Intern Med. 2010;170:1169–71.CrossRefPubMed Desai S, Brinker A, Swann J, Iyasu S. Sitagliptin associated drug allergy: review of spontaneous adverse event reports. Arch Intern Med. 2010;170:1169–71.CrossRefPubMed
2.
go back to reference Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRefPubMed Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRefPubMed
4.
go back to reference Stricklin SM, Stoecker WV, Rader RK, Hood AF, Litt JZ, Schuman TP. Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia). Dermatol Online J. 2012;18:9.CrossRefPubMed Stricklin SM, Stoecker WV, Rader RK, Hood AF, Litt JZ, Schuman TP. Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia). Dermatol Online J. 2012;18:9.CrossRefPubMed
5.
go back to reference Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012;26:249–53.CrossRefPubMed Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012;26:249–53.CrossRefPubMed
6.
go back to reference Nakatani K, Kurose T, Hyo T, Watanabe K, Yabe D, Kawamoto T, et al. Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin. Diabetes Ther. 2012;3:14.CrossRefPubMedPubMedCentral Nakatani K, Kurose T, Hyo T, Watanabe K, Yabe D, Kawamoto T, et al. Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin. Diabetes Ther. 2012;3:14.CrossRefPubMedPubMedCentral
7.
go back to reference Tanaka K, Ogawa Y, Shimada S. Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor. J Dermatol. 2012;39:726–8.CrossRefPubMed Tanaka K, Ogawa Y, Shimada S. Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor. J Dermatol. 2012;39:726–8.CrossRefPubMed
8.
go back to reference Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009;9:316–21.CrossRefPubMed Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009;9:316–21.CrossRefPubMed
9.
go back to reference Jung JW, Cho SW, Kim KH, Min KU, Kang HR. Clinical features of fixed drug eruption at a tertiary hospital in Korea. Allergy Asthma Immunol Res. 2014;6:415–20.CrossRefPubMedPubMedCentral Jung JW, Cho SW, Kim KH, Min KU, Kang HR. Clinical features of fixed drug eruption at a tertiary hospital in Korea. Allergy Asthma Immunol Res. 2014;6:415–20.CrossRefPubMedPubMedCentral
Metadata
Title
Fixed drug eruption to sitagliptin
Authors
Mrinal Gupta
Anish Gupta
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2015
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1186/s40200-015-0145-2

Other articles of this Issue 1/2015

Journal of Diabetes & Metabolic Disorders 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.